Plasma p-tau217 assays effectively predict amyloid status but lack precision for tau staging in Alzheimer's disease
{{output}}
Blood-based biomarkers for Alzheimer's disease (AD) have demonstrated high performance in identifying amyloid-β (Aβ) pathology. However, the diagnostic accuracy of commercial plasma biomarker assays in predicting PET-defined AD stages-particularly late-stag... ...
